Tag
The FDA is set to discuss reclassifying peptides for compounding, with telehealth companies like Mochi Health and Hims & Hers preparing to cash in on the anticipated regulatory shift, driven by political influence from HHS Secretary RFK Jr. and the GLP-1 boom.